
    
      OUTLINE:

        -  Induction therapy: Patients receive rituximab IV and cyclophosphamide IV over 30 minutes
           on day 1, bortezomib IV on days 1 and 8, and oral prednisone once daily on days 1-5.
           Treatment repeats every 21 days for up to 8 courses in the absence of disease
           progression or unacceptable toxicity. Patients then proceed to maintenance therapy.

        -  Maintenance therapy: Patients receive rituximab IV on days 1, 8, 15, and 22. Treatment
           repeats every 6 months for up to 4 courses in the absence of disease progression or
           unacceptable toxicity.

      After completion of study therapy, patients are followed every 4 months for 1 year, every 6
      months for 2 years, and then annually thereafter.
    
  